This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Heart failure	Chymase 1 mast cell (CMA1); angiotensin-converting enzyme (ACE)	<p>Studies in rodents suggest that dual CMA1 and ACE inhibitors could help treat heart failure. Both enzymes catalyze the production of angiotensin II, which plays a central role in regulating multiple renal and cardiovascular functions. In hamsters, a combination of ACE and CMA1 inhibitors improved cardiac function and increased survival following myocardial infarction (MI) compared with an ACE inhibitor alone. Next steps include testing the CMA1/ACE combination therapy in the clinic.</p> <p>SciBX 3(14); doi:10.1038/scibx.2010.432 Published online April 8, 2010</p>	<p>Dual inhibitor strategy patented by Teijin Pharma Ltd.; licensing status undisclosed Contact: Tune Kobayashi, Teijin Pharma Ltd., Tokyo, Japan e-mail: ts.kobayashi@teijin.co.jp</p>	<p>Wei, C. <i>et al. J. Clin. Invest.</i>; published online March 24, 2010; doi:10.1172/JCI39345 Contact: Hidenori Urata, Fukuoka University Chikushi Hospital, Fukuoka, Japan e-mail: uratah@fukuoka-u.ac.jp Contact: Louis J. Dell'Italia, The University of Alabama at Birmingham, Birmingham, Ala. e-mail: dell'Italia@physiology.uab.edu Contact: Ahsan Husain, Emory University, Atlanta, Ga. e-mail: ahusai2@emory.edu</p>